This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

47/100

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Mild cognitive impairment

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

SSRI treatment showed no significant effect on AD dementia progression (hazard ratio = 1.64, 95% confidence interval: 0.61 to 4.38) or cognitive trajectories, regardless of AD pathology. No significant differences in Aβ accumulation or cortical thickness were observed between SSRI users and non-users. External validation confirmed no significant SSRI effect on AD progression or cognitive decline. SSRI treatment was not associated with long-term cognitive effects in amnestic MCI, irrespective of underlying AD pathology. HIGHLIGHTS: SSRI treatment was not associated with long-term AD dementia risk in MCI. SSRI treatment had no impact on long-term cognitive performance changes in MCI. SSRI treatment did not affect Aβ accumulation or cortical thickness in MCI. SSRIs had no effect on MCI progression, regardless of underlying AD pathology.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study. This study found that SSRI treatment had no significant effect on progression to Alzheimer's disease dementia or cognitive trajectories in people with amnestic mild cognitive impairment, regardless of Alzheimer's pathology. SSRIs also did not affect amyloid accumulation or cortical thickness.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Li, Y., Liu, W., Wang, X., Qin, W., Liu, Z., Lyu, D., et al. (2025). Effect of SSRIs on clinical progression in amnestic mild cognitive impairment stratified by Alzheimer's disease pathology. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70946

Vancouver

Li Y, Liu W, Wang X, Qin W, Liu Z, Lyu D, et al. Effect of SSRIs on clinical progression in amnestic mild cognitive impairment stratified by Alzheimer's disease pathology. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70946. PMID: 41292493.

BibTeX

@article{li2025-41292493,
  author  = {Li, Yan and Liu, Wenying and Wang, Xuechu and Qin, Wei and Liu, Zhaojun and Lyu, Diyang and Li, Ying and Li, Bingqiu and others},
  title   = {{Effect of SSRIs on clinical progression in amnestic mild cognitive impairment stratified by Alzheimer's disease pathology}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70946},
  pmid    = {41292493},
  url     = {https://doi.org/10.1002/alz.70946}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: this is a follow-up (cohort) study. People are observed over time and not assigned to anything, so an association can reflect other differences between groups. Look at how long follow-up lasted, how many dropped out, and whether the authors adjusted for age, education and other health conditions.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded moderate. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Moderate means the abstract mentions a cohort, case-control or longitudinal design. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

SSRI treatment showed no significant effect on AD dementia progression (hazard ratio = 1.64, 95% confidence interval: 0.61 to 4.38) or cognitive trajectories, regardless of AD pathology.
No significant differences in Aβ accumulation or cortical thickness were observed between SSRI users and non-users.
External validation confirmed no significant SSRI effect on AD progression or cognitive decline.
SSRI treatment was not associated with long-term cognitive effects in amnestic MCI, irrespective of underlying AD pathology.
HIGHLIGHTS: SSRI treatment was not associated with long-term AD dementia risk in MCI.

Why it matters

This study found that SSRI treatment had no significant effect on progression to Alzheimer's disease dementia or cognitive trajectories in people with amnestic mild cognitive impairment, regardless of Alzheimer's pathology. SSRIs also did not affect amyloid accumulation or cortical thickness.

Study details

Study designlongitudinal study
Evidence strengthModerate

How this study scored 47/100

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record	2 / 4	Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design	7 / 12	A longitudinal study following the same people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 2 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.7 citations a year over 3 year(s) since 2025
Impact for its field and year	2 / 6	Cited 1.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Jianping Jia: h-index 61 (OpenAlex, whole career)
Institution's track record	1 / 3	National University of Singapore: institution h-index 1,166 (OpenAlex)
Multicenter collaboration	3 / 3	OpenAlex lists 10 institution(s) in 3 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41292493)
Free to read	2 / 2	Free to read
Total	47 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Mild cognitive impairment from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →